Trastuzumab for gastric cancer

Expert Opinion on Biological Therapy
Judith Meza-JuncoMichael B Sawyer

Abstract

Gastric cancer is a disease with different management approaches in different regions, especially between Western and Asian countries. Surgery is the mainstay of treatment for non-metastatic disease. Perioperative chemotherapy or adjuvant radio-chemotherapy is recommended, since recurrences are common after curative resection. Unfortunately, advanced or metastatic gastric cancer constitutes the majority of patients in clinical practice. For these patients systemic chemotherapy is the standard treatment, to provide palliation and prolong survival; however, prognosis remains poor. Several molecular targeting agents are under evaluation in international randomized studies. To review chemotherapy and targeted therapies for gastric cancer, chemical and pharmacological characteristics of trastuzumab, and evidence for its clinical use in gastric cancer. Examination of relevant literature. HER-2 is overexpressed/amplified in approximately 22% of gastric cancer patients. Trastuzumab, a recombinant humanized anti-HER-2 monoclonal antibody, is, to our knowledge, the first biological therapy that has showed a survival improvement by nearly 3 months (reduced risk of death by 26%), thus trastuzumab in combination with chemotherapy is a treat...Continue Reading

References

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P CarterH M Shepard
Feb 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusR Heuman
Jun 23, 1998·Anti-cancer Drugs·S CascinuG Catalano
Nov 27, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E Van CutsemJ Wils
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SeidmanDeborah Keefe
Sep 26, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian Leyland-JonesParviz Ghahramani
Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TannerJ Isola
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaParviz Ghahramani
Apr 16, 2005·Clinical Oncology : a Journal of the Royal College of Radiologists·D WilsonJ I Geh
May 4, 2005·Cancer Chemotherapy and Pharmacology·Rene BrunoPamela Klein
Jul 7, 2005·Postgraduate Medical Journal·M Inoue, S Tsugane
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna D WagnerWolfgang E Fleig
Jul 11, 2006·The New England Journal of Medicine·David Cunningham MAGIC Trial Participants
Oct 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomislav DragovichJames L Abbruzzese
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemUNKNOWN V325 Study Group
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manish A ShahDavid P Kelsen
Dec 14, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C PintoA A Martoni
Jan 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G ValabregaM Aglietta
Apr 24, 2007·Acta Oncologica·Theodoros FoukakisPehr A Lind
Jul 6, 2007·The New England Journal of Medicine·Clifford A Hudis
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniUNKNOWN V-325 Study Group
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniUNKNOWN V-325 Study Group
Nov 6, 2007·The New England Journal of Medicine·Shinichi SakuramotoUNKNOWN ACTS-GC Group
Jan 4, 2008·The New England Journal of Medicine·David CunninghamUNKNOWN Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom
Jan 19, 2008·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Kiyoshi HasegawaMasatoshi Makuuchi
Feb 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zhifu SunPing Yang
Mar 15, 2008·Pharmacoepidemiology and Drug Safety·V GonzálezG Manso
May 7, 2008·Journal of Gastroenterology·Atsushi Ohtsu
Jul 18, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A CervantesE Rodríguez-Braun
Aug 5, 2008·Gastrointestinal Endoscopy Clinics of North America·Kentaro Sugano
Oct 8, 2008·Annals of the New York Academy of Sciences·Fayez T Hammad
Dec 2, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Peter S Hall, David A Cameron

❮ Previous
Next ❯

Citations

May 19, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J C HaanB Ylstra
Sep 10, 2013·Journal of Hematology & Oncology·Amikar Sehdev, Daniel V T Catenacci
Nov 18, 2010·Drugs·Jamie D Croxtall, Kate McKeage
Aug 6, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Jamie D Croxtall, Kate McKeage
Dec 29, 2010·Pathology Research International·Cathy B MoelansG Johan A Offerhaus
Apr 10, 2013·Critical Reviews in Oncology/hematology·Constance ThibaultYazid Belkacémi
Apr 17, 2012·Gynecologic Oncology·Flora ZagouriRupert Bartsch
Jun 17, 2011·Cancer Treatment Reviews·Flora ZagouriDimitrios Pectasides
May 22, 2010·Cancer Letters·William K K WuJoseph J Y Sung
Feb 11, 2014·Asian Pacific Journal of Tropical Medicine·Hong-Wen WuWen-Kun Bai
Jul 20, 2016·Journal of Gastric Cancer·Fatma Yalçin MüsriMehmet Artaç
May 10, 2016·World Journal of Gastroenterology : WJG·Mehmet MihmanliUygar Demir

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
C Gravalos, A Jimeno
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Angélica Nogueira-RodriguesCarlos G Ferreira
© 2022 Meta ULC. All rights reserved